FDA Approves RHHBY Gazyva for Childhood Nephrotic Syndrome

The FDA approved Genentech’s Gazyva (obinutuzumab) on September 25 to reduce the risk of relapse in adults and children ages 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome (INS) who are in remission. It is the first FDA-approved anti-CD20 antibody for the disease; rituximab has been used off-label for years.

Roche’s ADR (RHHBY) closed at $54.45. The approval rests on INSHORE (NCT05627557), a Phase 3 open-label study of 85 patients ages 2 to 25 randomized to obinutuzumab or mycophenolate mofetil (MMF). Obinutuzumab hit the primary endpoint: 95.5% of patients stayed in complete remission through week 52 versus 73.2% on MMF, an adjusted difference of 23.36 percentage points (P=.003). It also cut the risk of relapse or death by 75% (hazard ratio 0.25) and produced 4 relapses versus 23. The result is unusually clean for a nephrology trial: a 23-point gap in sustained remission and a 75% cut in relapse risk in a disease where every relapse erodes kidney function over time.

Mechanism: Why a Type II Anti-CD20 Works Where Steroids Keep Failing

Gazyva is a Type II, glycoengineered anti-CD20 antibody that depletes B cells more thoroughly than first-generation rituximab, which is why it can work where steroid tapering keeps failing. The glycoengineering (removing fucose from the Fc region) increases affinity for Fc-gamma receptors on immune effector cells, and Type II binding kills B cells through a mechanism that includes direct cell death signaling, not just complement and antibody-dependent killing. In INS, the working hypothesis is that B cells, possibly via pathogenic antibodies or antigen presentation, drive the relapsing podocyte injury that spills protein into urine. Remove the B cells thoroughly and the relapse cycle breaks — the same logic that made rituximab a beloved off-label tool, now with a molecule engineered to do the job better.

Rituximab, the older anti-CD20, is used off-label for these children but has no approved label, which means inconsistent insurance coverage and dosing. An approved product with pediatric trial data behind it standardizes all of that overnight.

The Disease and the Unmet Need

INS is the most common primary glomerular disease in children, affecting roughly 1-4 per 100,000 each year. Steroid dependence carries real long-term harm: repeated prednisone courses stunt growth and thin bones, so a steroid-sparing option is the unmet need. That framing matters for adoption — physicians are not just comparing Gazyva to MMF, they are comparing it to another decade of cumulative steroid toxicity in a growing child.

This is a label expansion, not a first approval: Gazyva already carries indications in chronic lymphocytic leukemia, follicular lymphoma, and lupus nephritis. The INS approval is Roche’s second renal indication for Gazyva after lupus nephritis, with pMN a potential third, turning a blood-cancer drug into a nephrology franchise.

What It Means for the Trade

For Roche, a mega-cap, the commercial impact is small. RHHBY at $54.45 moves on oncology pipelines and currency, not a pediatric nephrology niche. The strategic read is the pattern: Roche is systematically converting Gazyva from an oncology asset into a B-cell-driven autoimmune and renal franchise, with each approval expanding the prescriber base from hematologists to nephrologists and pediatricians. As with any B-cell-depleting therapy, the label carries infusion-related reactions and infection risk.

The more tradeable signal is downstream. Watch the separate Gazyva filing in primary membranous nephropathy, under Priority Review with a PDUFA date expected by November 2026. There, the Phase 3 MAJESTY study (NCT04629248) showed Gazyva beat tacrolimus on complete remission at two years, and an approval would make it the first FDA-approved therapy for that disease. A second renal approval in two months would cement the franchise narrative.

Risks and What Could Go Wrong

The open-label design of INSHORE means patients and investigators knew assignments — a known bias risk in remission-maintenance trials, though the magnitude here (23 points) makes bias an unlikely full explanation. Long-term B-cell depletion in growing children carries infection and vaccine-response questions that longer follow-up will have to address. And adoption is the real swing factor: whether physicians shift from off-label rituximab, which is cheap and familiar, to an approved anti-CD20, which is what makes this more than a footnote on Roche’s nephrology calendar. If payers push back on price versus off-label rituximab, uptake could be slower than the data deserve.